IMPACT研究:吸入糖皮质激素撤药与基线治疗对慢阻肺急性加重的影响
IMPACT试验的事后分析评估了既往ICS使用对FF/UMEC/VI疗效的影响。结果显示,FF/UMEC/VI较UMEC/VI显著降低既往ICS使用者的中重度急性加重率(29%),非使用者仅见数值下降(12%,P=0.115)。排除前30天分析仍显著(19%),且严重加重率获益与既往ICS无关,提示疗效非源于突然撤药。
要点
- FF/UMEC/VI较UMEC/VI显著降低既往ICS使用者的中重度急性加重率29%。
- 排除前30天分析,FF/UMEC/VI仍显著降低中重度急性加重率19%。
- 严重加重率获益与既往ICS使用无关,排除前30天仍显著降低29%。
核心结论
- FF/UMEC/VI对急性加重、肺功能和生活质量的改善似乎与突然撤除ICS无关。
研究设计与样本
- IMPACT随机双盲多中心临床试验的事后分析,按既往ICS使用分层。
主要发现
- 既往ICS使用者中,FF/UMEC/VI较UMEC/VI显著降低中重度急性加重年率29%(P<0.001)。
- 既往ICS非使用者中,FF/UMEC/VI较UMEC/VI仅数值降低中重度急性加重年率12%(P=0.115)。
- 排除前30天数据后,FF/UMEC/VI较UMEC/VI显著降低治疗中中重度急性加重年率19%(P<0.001)。
- 严重急性加重率:既往ICS使用者降低35%(P<0.001),非使用者降低35%(P=0.018),排除前30天总体降低29%(P<0.001)。
- 无论既往ICS使用与否,FF/UMEC/VI较UMEC/VI的 trough FEV1 和 SGRQ 改善全程维持。
临床怎么用
- 对于有急性加重史的症状性慢阻肺患者,FF/UMEC/VI较UMEC/VI可降低急性加重,且获益不依赖于突然撤除ICS。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: In the IMPACT (Informing the Pathway of Chronic Obstructive Pulmonary Disease Treatment) trial, fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) significantly reduced exacerbations compared with FF/VI or UMEC/VI in patients with symptomatic chronic obstructive pulmonary disease and a history of exacerbations.Objectives: To understand whether inhaled corticosteroid (ICS) withdrawal affected IMPACT results, given direct transition from prior maintenance medication to study medication at randomization.Methods: Exacerbations and change from baseline in trough FEV1 and St. George's Respiratory Questionnaire results were analyzed by prior ICS use. Exacerbations were also analyzed while excluding data from the first 30 days.Measurements and Main Results: FF/UMEC/VI significantly reduced the annual moderate/severe exacerbation rate compared with UMEC/VI in prior ICS users (29% reduction; P < 0.001), but only a numerical reduction was seen among prior ICS nonusers (12% reduction; P = 0.115). To minimize impact from ICS withdrawal, in an analysis excluding the first 30 days, FF/UMEC/VI continued to significantly reduce the annual on-treatment moderate/severe exacerbation rate (19%; P < 0.001) compared with UMEC/VI. The benefit of FF/UMEC/VI compared with UMEC/VI was seen for severe exacerbation rates, regardless of prior ICS use (prior ICS users, 35% reduction; P < 0.001; non-ICS users, 35% reduction; P = 0.018), and overall when excluding the first 30 days (29%; P < 0.001). Improvements from baseline with FF/UMEC/VI compared with UMEC/VI were also maintained throughout the study for both trough FEV1 and St. George's Respiratory Questionnaire, regardless of prior ICS use.Conclusions: These data support the important treatment effects of FF/UMEC/VI combination therapy on exacerbation reduction, lung function, and quality of life that do not appear to be related to abrupt ICS withdrawal.Clinical trial registered with www.clinicaltrials.gov (NCT02164513).
引用
- Han MK, Criner GJ, Dransfield MT, et al. The Effect of Inhaled Corticosteroid Withdrawal and Baseline Inhaled Treatment on Exacerbations in the IMPACT Study. A Randomized, Double-Blind, Multicenter Clinical Trial. Am J Respir Crit Care Med. 2020. PMID: 32584168. doi:10.1164/rccm.201912-2478OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。